Takahashi, Shin http://orcid.org/0000-0001-6695-3099
Fukui, Takafumi
Nomizu, Tadashi
Kakugawa, Yoichiro
Fujishima, Fumisyoshi
Ishida, Takanori
Ohuchi, Noriaki http://orcid.org/0000-0001-8357-8761
Ishioka, Chikashi http://orcid.org/0000-0002-3023-1227
Funding for this research was provided by:
Japan Society for the Promotion of Science (24701000)
Miyagi Health Care Association (no grant number)
Article History
Received: 12 December 2020
Accepted: 7 April 2021
First Online: 24 July 2021
Declarations
:
: Dr. Takahashi reports personal fees from Taiho, Chugai, Asahikasei, Bayer, Japan blood products organization, Medicon, Termo, Sanofi, Nippon-kayaku, Takeda, Yakult, grants and personal fees from Merckbiopharma, grants from Ono, outside the submitted work; In addition, Dr. Takahashi has a patent JP4370409B2 issued. Dr. Ishida reports grants from Taiho, Eisai and Kyowa-Kirin, grants and personal fees from Chugai, personal fees from Pfizer and Astra Zeneca, outside the submitted work. Prof. Ishioka reports grants and personal fees from Novartis, Daiichi Sankyo, Bayer, Bristol-Myers Squibb, Nippon-Kayaku, Hitachi, personal fees from Taiho, Ono, Merckbiopharma, AsahiKasei, Sanofi, Takeda, Eisai, Eli Lilly, Mundipharma, Teijin, Chugai, Konica Minolta, Pfizer, Mochida, grants from Riken Genesis, MSD, Linical, outside the submitted work; In addition, Prof. Ishioka has a patent JP4370409B2 issued. All the remaining authors have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.